Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
Key facts
- Who runs it
- Primus Pharmaceuticals
- Where
- Annandale, Auburn, Aventura, Boca Raton, Clearwater, Clovis, Colleyville, Coral Springs, Crossville, Fayetteville, Harlingen, Jupiter, Loxahatchee Groves, Margate, Mesquite, Miami, Miami Beach, Oldsmar, Red Oak, South Miami, Springboro, Sterling Heights, Stockbridge, and Valley Village, United StatesSee the 24 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 50 people, planned
- Started
- 15 Nov 2023
- Planned end
- 15 Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metaxalone 640 mg Oral Tablet
- Record updated
- 14 September 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- No clinically significant conditions impacting quality or quantity of pain
- Baseline Numeric Pain Scale ≥ 6
- Capable of answering text or email survey reminders
- Low back pain with or without sciatica
Who cannot take part
- Current use of cimetidine or monoamine oxidase inhibitors
- Current use of other skeletal relaxants
- Current use of other pain relievers
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in United States.
- Northern Virginia Center for ArthritisAnnandale, United StatesContact: S SodhiNo longer taking part
- East Alabama Arthritis CenterAuburn, United StatesContact: S SodhiNo longer taking part
- Arthritis and Osteoporosis CenterAventura, United StatesContact: S SodhiNo longer taking part
- William Sunshine, MDBoca Raton, United StatesContact: S SodhiNo longer taking part
- Robert Levin, MDClearwater, United StatesContact: S SodhiTaking people
- Jayashree Sinha, MD 1Clovis, United StatesContact: S SodhiNo longer taking part
- Heritage Rheumatology & Arthritis CareColleyville, United StatesContact: S SodhiTaking people
- 5. CZ RheumatologyCoral Springs, United StatesContact: S SodhiTaking people
- Cumberland RheumatologyCrossville, United StatesContact: Sivalingam Kanagasegar, MDTaking people
- Carolina RheumatologyFayetteville, United StatesContact: S SodhiNo longer taking part
- Integrative Rheumatology of South TexasHarlingen, United StatesContact: S SodhiNo longer taking part
- 4. Palm Beach Rheumatology and WellnessJupiter, United StatesContact: S SodhiNo longer taking part
- Family Arthritis CenterLoxahatchee Groves, United StatesContact: S SodhiNo longer taking part
- Arthritis and Rheumatology Center of South FloridaMargate, United StatesContact: S SodhiNo longer taking part
- Southwest Research GroupMesquite, United StatesContact: S SodhiNo longer taking part
- Arthritis and Osteoporosis Treatment and ResearchCenterMiami, United StatesContact: George Munoz, MDTaking people
- CZ RheumatologyMiami Beach, United StatesContact: Conrad Ziembinski, DOTaking people
- Bay Area RheumatologyOldsmar, United StatesContact: Rodney Daniel,, MDTaking people
- DFW RheumatologyRed Oak, United StatesContact: S SodhiNo longer taking part
- Arthritis and Rheumatic Care CenterSouth Miami, United StatesContact: S SodhiNo longer taking part
- Ohio Arthritis and Osteoporosis Center of Southwest OhioSpringboro, United StatesContact: S SodhiNo longer taking part
- Arthritis and Rheumatology Center of MISterling Heights, United StatesContact: Srijana Bakshi, MDTaking people
- Arthritis Research and Treatment CenterStockbridge, United StatesContact: S SodhiNo longer taking part
- Sean Wollaston, MDValley Village, United StatesContact: S SodhiNo longer taking part
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about:
Read full original descriptionShow less
* Amount and quality of pain * Interference with physical activity * Interference with sleep
The 2 groups in the trial
- Active M640Existing treatment, for comparison
Metaxalone micronized 640 mg over encapsulated tablet Taken orally every 6 hours for 7 days
Treatment: Metaxalone 640 mg Oral Tablet
- PlaceboPlacebo, for comparison
Inactive placebo capsule 640 mg Taken orally every 6 hours for 7 days
Treatment: Metaxalone 640 mg Oral Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Modified Release Metaxalone 640 mg in Acute Lumbosacral Musculoskeletal Conditions With Spinal Stenosis and Sciatica
- Criteria questions
- Built from NCT06157177, who can take part
- Record updated
- 14 September 2026